Cetuximab beta, sold under the brand name Enlituo, is a monoclonal antibody used for the treatment of colorectal cancer.
Cetuximab beta was approved for medical use in China in June 2024.
Medical uses Cetuximab beta is indicated for use in combination with the FOLFIRI chemotherapy regimen as a first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer.
Society and culture Legal status Cetuximab beta was approved for medical use in China in June 2024.
Names Cetuximab beta is the international nonproprietary name.
Cetuximab beta is sold under the brand name Enlituo.
References